In pregnant women, tyrosine kinase inhibitors may represent a novel therapeutic option.[57] Furthermore, high PD-L1 expression in ALK-negative IMT highlights the potential of immune checkpoint pathways as therapeutic targets in recurrent or refractory disease.[58,59] Targeted therapies generally provide better efficacy and a more favorable safety profile than conventional chemotherapy, making them preferred options for precision treatment in ALK-negative IMT. Here, CD274 is linked to inflammatory myofibroblastic tumor.